Unibest
← Back to patent-cliff list

DNN.65.21.005

Tier C — Watch / trade

DNN.65.21.005

Ache Laboratorios Farmaceuticos Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:Updating

Indications (approved):Benign prostatic hyperplasia

Regional status

US
-
EU
-
China
-
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of DNN.65.21.005?

Approved indications include: Benign prostatic hyperplasia.

When does the DNN.65.21.005 patent expire?

No public expiry year is available for DNN.65.21.005 yet; this page updates once verified.

How do I get a quote for DNN.65.21.005 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29